Kiromic BioPharma (OTC:KRBP) Stock, Quote.Headers.trade-ideas

Kiromic BioPharma

Kiromic BioPharma Inc is a biotechnology company. It is an artificial intelligence (AI) driven, end-to-end allogeneic cell therapy company, currently developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company is a gene-editing which utilizes artificial intelligence and a proprietary neural network platform with a therapeutic focus on immuno-oncology.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AAOI

ACCD

ALVO

APPS

APYX

ATXG

AUPH

BACK

BTTR

BXRX

CBAY

CNVS

CTMX

EIGR

EOSE

EVLO

FHTX

FLWS

GSUN

HILS

iMedia Brands, Inc. - 8.5% Senior Notes Due 2026

IMBIL

KRBP

Kintara Therapeutics, Inc. - Common Stock

KTRA

MVIS

Nuveen California Dividend Advantage Municipal Fund 2

OTRK

PALT

PIII

RNLX

ROOT

SRGA

UNCY

XPEV

Gainers


	Addentax Group Corp. (NASDAQ: ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.


Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

AWIN

GNFT

LGHL

MICS

SCOR

SISI

TRUP

WAVE

Gainers


	Renalytix Plc (NASDAQ: RNLX) shares surged 48.7% to $3.02 in pre-market trading after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.


Why Renalytix Are Trading Higher By Over 48%; Here Are 20 Stocks Moving Premarket

Biotech

Health Care

General

Kiromic BioPharma Inc (NASDAQ: KRBP) shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22.

What&#39;s Going On With Kiromic BioPharma Stock Wednesday

KIROMIC BIOPHARMA INC by Kiromic BioPharma, Inc.

Kiromic BioPharma Inc

Alternus Clean Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) ("Alternus"), announces that on October 3, 2024, by mutual agreement and in furtherance of the Company's balance sheet improvement activities, Solis Bond Company DAC ("Solis"), a company formed under the laws of Ireland and an indirect wholly owned subsidiary of the Company, was sold, along with its subsidiaries in Romania, to Solis Trustee Special Vehicle Limited, the Solis Bondholders' ownership vehicle, for one Euro (€1.00) in accordance with the terms of the Solis Bonds, as amended.
As a result of the sale, Alternus has removed approximately $100 million in debt and payables related to Solis activities and will improve shareholders equity by approximately $45 million. Solis accounted for 98% of group revenues for the six months ended June 30, 2024. Alternus will record the sale as discontinued activities as it has no business activities in Romania.

Financing

ALCE

Alternus Sheds $100M Of Debt And Payables, And Payables Related To Solis Activities And Will Improve Shareholders Equity By ~$45M From Disposal Of Certain Subsidiaries

Contracts

KOPN

Kopin Announces Production Purchase Order For SXGA-R15 Microdisplay System From Mirtec; Size Not Disclosed

Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) stock continued its rally Tuesday after closing higher by over 11% on Monday.
The stock rally marks Republican presidential candidate Donald Trump&#8217;s&nbsp;return to Butler, Pennsylvania, the site of his&nbsp;July 13 assassination attempt, for a campaign rally with Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) chief&nbsp;Elon Musk, CNBC <a target="_blank" href="https://www.cnbc.com/2024/10/07/djt-trump-media-elon-musk-butler-rally.html" rel="noreferrer noopener">reports</a>.
In Butler, Musk&nbsp;endorsed Trump, including chanting his political slogan, &#8220;Make America Great Again,&#8221; during Trump&#8217;s&nbsp;90-minute speech. Musk has been a vocal supporter of the Trump campaign since the July assassination attempt.
Trump retained his majority stock in the Truth Social parent, signaling his conviction in the stock while its co-founders cashed out.
Musk also created a pro-Trump political action committee, America PAC. Trump also promised to form a Musk-proposed&nbsp;government efficiency commission to cut waste throughout the federal government.
Trump Media stock <a target="_blank" href="https://www.benzinga.com/government/24/10/41212461/whats-going-on-with-trump-media-technology-stock-on-monday" rel="noreferrer noopener">also benefited from</a> the Supreme Court&#8217;s refusal to hear a case linked to Trump&#8217;s social media account data. The case originated from special counsel Jack Smith&#8217;s probe into Trump&#8217;s alleged election interference in 2020.
Trump kept attacking the Biden administration with his pro-America policies while <a target="_blank" href="https://www.benzinga.com/government/24/10/41171273/whats-going-on-with-trump-media-technology-stock-on-thursday" rel="noreferrer noopener">reports indicated the</a> Biden government&#8217;s inflation and border security policies weighed against his chances.
The Financial Times <a target="_blank" href="https://www.ft.com/content/2c5167c1-7163-4bc4-8746-fdac7250ef78a" rel="noreferrer noopener">reported</a> that Trump&#8217;s presidential victory and policies, including lower corporate taxes and tariffs&nbsp;on imported goods, could raise the&nbsp;federal debt by $7.5 trillion through 2035.
Conversely, Democratic candidate and VP Kamala Harris&#8217;s policies, including tax credits for small businesses and access to affordable childcare and housing,&nbsp;could increase the debt by $3.5 trillion.
Trump Media stock gained 7% in the last five days.
Price Action: DJT stock is up 4.40% at $19.20 premarket at the last check on Tuesday.
Image via Shutterstock

Government

Media

TSLA

Trump Media Stock Surges as Elon Musk Backs Trump at Pennsylvania Event

Study Evaluates Incidence, Severity, And Management Of Diarrhea In 75 Breast Cancer Patients Using Targeted Therapies With Or Without Chemotherapy Based On Patient-Reported Outcomes

JAGX

Jaguar Health Submits Late-Breaking Abstract For Study On Impact Of Diarrhea From Cancer Therapies In Breast Cancer Patients Receiving Placebo During OnTarget Phase 3 Trial

CURB's Non-Heating Device Uses Ultrasonic Vibrations For Maximum Absorption; Products Expected To Be Available For Order Starting Nov 15 Through Greenlane's Online Retail Stores And Wholesale Portal

GNLN

Greenlane Announces Non-Binding LOI To Distribute CURB Lifestyle's Patented Inhalation Device For Nicotine, Cannabinoids, And Wellness Compounds Across US, Canada, Latin America, And EU

Guidance

LakeShore Biopharma Sees Prelim. 1H Revenue RMB350M-RMB380M, Representing 28-39% Growth

Northland Capital Markets analyst Ted Jackson reiterates Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) with a Outperform and maintains $30 price target.

Price Target

Reiteration

Analyst Ratings

Northland Capital Markets Reiterates Outperform on Mayville Engineering, Maintains $30 Price Target

RBC Capital analyst Tom Narayan maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Outperform and raises the price target from $224 to $236.

RBC Capital Maintains Outperform on Tesla, Raises Price Target to $236

Reports Full Principal Repayment Of $75M Loan From CloudPay And $10M Assignment Of Airship Group Investment To JV; Portfolio Now Includes 49 Debt Investments In 32 Companies And 86 Equity Investments In 53 Companies

RWAY

Runway Growth Finance Provides Q3 2024 Portfolio Update With $75.3M In Funded Investments Across Seven New And Existing Portfolio Companies; Includes $23M To Snap! Mobile, $45.3M To Zinnia Corporate Holdings, And $20M To Elevate Services

Northland Capital Markets analyst Bobby Brooks maintains Groupon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRPN#NASDAQ">GRPN</a>) with a Outperform and maintains $20 price target.

GRPN

Northland Capital Markets Maintains Outperform on Groupon, Maintains $20 Price Target

AISP

Airship AI Holdings Awarded $1.2M Contract From A Transportation & E-Commerce Company For Acropolis Enterprise Video And Data Management Platform

Airship AI Announces $1.2M Contract Award With Fortune 100 Transportation And E-Commerce Company For Support And Maintenance Of Acropolis Enterprise Video And Data Management Platform Over Next Nine Months To Support Global Operational And Physical Security Requirements

Macro Economic Events

Econ #s

Economics

US Aug. Imports $342.20BB, Exports $271.80BB

Partnership To Enhance Hub Group's Intermodal Business And Drayage Capabilities In Mexico, Creating Largest Cross-Border And Intra-Mexico Intermodal Company; Expected To Be Immediately Accretive To 2024 EPS

HUBG

Hub Group Announces Joint Venture With Mexico-Based EASO To Expand Mexico Intermodal And Cross-Border Service Offering

TNXP

Tonix Pharmaceuticals Enters AI And ML Research Collaboration With X-Chem To Develop Broad-Spectrum Antivirals

USA Trade Balance For August -70.40B Vs -70.10B Est.; -78.90B Prior

Northland Capital Markets analyst Tim Savageaux maintains Aviat Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) with a Outperform and lowers the price target from $40 to $35.

AVNW

Northland Capital Markets Maintains Outperform on Aviat Networks, Lowers Price Target to $35

On Tuesday, Oragenics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) said it has completed a key study for its new concussion drug, ONP-002.
What Happened: A recent study shows that the drug successfully targets areas inside the nose connected to the brain, making the drug more likely to reach and treat the brain after a concussion.
In the study, ONP-002 was tested using a nasal spray device. The goal of intranasal casting studies is to identify where the drug lands inside a cast metal anatomical model of the interior nose.
The model is standard for intranasal drug delivery and is accepted by the FDA as a surrogate for the actual nasal passage.
The results showed that the drug spreads well in the nose areas, where it can be quickly absorbed into the brain.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40483692/exclusive-oragenics-completes-spray-dry-drug-manufacturing-intranasal-device-filling-for-anticipa" rel="noreferrer noopener">EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury</a>.
Why It Matters: Oragenics is now preparing to move forward with human testing (Phase 2) in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug within 8 hours of the injury.
&#8220;In preparing for our Phase 2 study, we wanted to study whether our nasal spray device would give ONP-002 an increased chance of reaching the brain quickly after a concussion. The study results are promising, as they show the drug targets areas in the nose directly linked to the brain. This should increase the chances of the drug being effective in treating concussion and reduces the likelihood of it being swallowed, which is another encouraging sign,&#8221; said Michael Redmond, President of Oragenics.
In August, Oragenics completed a study that indicates ONP-002 does <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40251272/exclusive-oragenics-concussion-drug-clears-fda-required-cardiotoxicity-testing-planning-for-phase" rel="noreferrer noopener">not cause cardiotoxicity</a>.
A concussion&nbsp;is a mild traumatic brain injury that affects brain function, with an estimated 69 million cases reported annually worldwide.
Long-term symptoms can develop in up to 20% of patients. Currently, there is no pharmaceutical treatment for concussions.
Price Action: OGEN stock closed at $0.39 on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41214188/reviva-pharmaceuticals-schizophrenia-drug-demonstrates-strong-efficacy-on-heels-of-" target="_blank" rel="noreferrer noopener">Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst</a></li>
</ul>

Market-Moving Exclusives

Exclusives

OGEN

EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate

EXCLUSIVE: Oragenics Tells Benzinga 'Oragenics is now preparing to move forward with human testing (Phase II) in patients who come to the emergency room with a concussion, aiming to give the first dose of the drug  within 8 hours of the injury'

EXCLUSIVE: Oragenics Tells Benzinga Co. Completes Key FDA Recognized Study For ONP-002

Kiromic Biopharma (KRBP) has released an update. Kiromic BioPharma, Inc. has secured a financial boost by issuing a Senior Secured Convertible Prom...

Kiromic Biopharma Strikes $2M Convertible Debt Deal for Growth

Kiromic BioPharma files to withdraw registration statement

Kiromic Biopharma (KRBP) has issued an announcement. Kiromic BioPharma, Inc. is gearing up to share its corporate vision and strategy through a ser...

Kiromic Biopharma Outlines Vision in Stakeholder Meetings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the first quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -$1.00.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/krbp-stock-earnings-kiromic-biopharma-for-q1-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q1 2024

The latest update is out from Kiromic Biopharma (KRBP). Kiromic BioPharma, Inc. has reached an agreement to transform $7.2 million of its high-inte...

Kiromic BioPharma's Strategic Financial Restructuring and Equity Shift

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Kiromic BioPharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/krbp-stock-quote/">KRBP</a>) just reported results for the second quarter of 2024.<ul><li>Kiromic BioPharma reported earnings per share of -74 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/krbp-stock-earnings-kiromic-biopharma-for-q2-of-2024/">KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

KRBP Stock Earnings: Kiromic BioPharma Reported Results for Q2 2024

Kiromic stock soars 65% on FDA fast track status for Deltacel

Press Releases

Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial

Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial

Kiromic BioPharma to Advance Deltacel-01 Clinical Trial to Part 2, Expansion Phase

Kiromic BioPharma Reports 20% Tumor Size Reduction at Eight Months in First Patient Enrolled in Deltacel-01

Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial

Kiromic BioPharma's Deltacel Receives FDA Fast Track Designation

Kiromic BioPharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation

Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial

Kiromic BioPharma Reports Favorable 10-Month Follow-Up Results for the First Patient Treated in its Deltacel-01 Clinical Trial

Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Kiromic BioPharma

Kiromic BioPharma (KRBP) Forecast

Kiromic BioPharma (OTC:KRBP) Stock, Quote.Headers.trade-ideas